<DOC>
	<DOCNO>NCT00912860</DOCNO>
	<brief_summary>To evaluate immunogenicity serum-free pre-formulated solution Avonex give interferon beta naive patient relapsing/remitting multiple sclerosis .</brief_summary>
	<brief_title>Immunogenicity Safety Study Serum-Free Avonex</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Must diagnosis relapsing/remitting MS define McDonald , et al15 ; criterion number 14 . Must expand disability status scale ( EDSS ) score 0 5.5 , inclusive . Must able understand comply protocol . Has experience relapse within 2 month prior Day 1 . Relapses define new recurrent neurologic symptom associate fever infection , last least 48 hour , accompany new objective neurological finding upon examination investigator . History significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease would preclude therapy interferon beta . Abnormal screen baseline blood test determine clinically significant investigator History seizure within 3 month prior Day 1 . History suicidal ideation within 3 month prior Day 1 episode severe depression within 3 month prior Day 1 . Known allergy natural rubber latex . Other inclusion exclusion criterion apply per protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>interferon beta-1a</keyword>
	<keyword>avonex</keyword>
</DOC>